These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis

No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.

Johnson & Johnson Rises on $572 Million Fine That's Smaller Than Feared

Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Why Macy's Is at Risk of Losing Its Shirt

Earnings misses, bad planning, and product-line execution problems are all hitting the retailer, but it's the macro woes that will also hurt its competitors.

Earnings to Tell Whether Cannabis' High Growth Story Is Going to Pot

After a 2018 high, marijuana stocks are gaining popularity again, but which ones are producing the most green for investors? Here are the charts.

A Look at Mylan's New Post-Merger Management

What new management means for Mylan shareholders moving forward.

Mylan Jumps on Deal With Pfizer to Form New Company

Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.

Alphabet Shares Soar After Excellent Earnings Results

A big jump in the market cap of Google's parent is in store thanks to an impressive second-quarter report.

Tesla Tanks as Profitability Problems Persist, Another Executive Exits

Volatility reigns once again at the electric carmaker, which is seeing JB Straubel depart as chief technology officer.

Interesting Small-Cap Charts Are Developing Into Earnings

Big-cap names have been driving the market, but some small-caps could make noise, too.